New combo attack on lung cancer: drug plus local therapy may delay progression

This study tests whether adding a local treatment (like radiation or ablation) to the standard drug osimertinib can better control advanced EGFR-mutated lung cancer. About 64 adults with stable disease after 3-6 months on osimertinib and up to 3 remaining active spots will be randomly assigned to continue the drug alone or add local therapy. The goal is to see if the combination improves the chance of staying progression-free at 18 months.